Dr. Peter Hotez with Dr. Maria Elena Bottazzi. Photo courtesy of TMC

Houston vaccine scientist Dr. Peter Hotez can add one more prize to his shelf.

Hotez — dean of the National School of Tropical Medicine and professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, co-director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics — is no stranger to impressive laurels. In 2022, he was even nominated for a Nobel Peace Prize for his low-cost COVID vaccine.

His first big win of 2025 is this year’s Hill Prize, awarded by the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

Hotez and his team were selected to receive $500,000 from Lyda Hill Philanthropies to help fund The Texas Virosphere Project. The endeavor was born to help create a predictive disease atlas relating to climate disasters. Because the climate crisis has ushered in changes to the distribution of diseases, including dengue, chikungunya, Zika, Chagas disease, typhus and tick-borne relapsing fever, it’s important to predict outbreaks before they become a menace.

Rice University researchers are collaborating with Hotez and his team on a project that combines climate science and metagenomics to access 3,000 insect genomes. The goal is to aid health departments in controlling disease and informing policy.

The Hill Prize, which is being awarded to six innovators for the first time, thanks to a $10 million commitment from the philanthropic organization, is intended to back ideas that are high-risk and high-reward. Each of the projects was chosen for its potential real-life impact on some of Texas's — and the world’s — most challenging situations. Hotez’s prize is the first Hill Prize to be given in the realm of public health. The additional winners are:

  • Hill Prize in Medicine: Kenneth M. Hargreaves, D.D.S., Ph.D., The University of Texas Health Science Center at San Antonio
  • Hill Prize in Engineering: Joan Frances Brennecke, Ph.D. (NAE), The University of Texas at Austin
  • Hill Prize in Biological Sciences: David J. Mangelsdorf, Ph.D. (NAM, NAS), UT Southwestern Medical Center
  • Hill Prize in Physical Sciences: James Chelikowsky, Ph.D., The University of Texas at Austin
  • Hill Prize in Technology: Robert De Lorenzo, M.D., EmergenceMed, LLC
Read about other Houston-area researchers recognized by TAMEST here.
Houston's Nobel Prize winner, Jim Allison, is the star of Breakthrough, which premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Photo via SXSW.com

Documentary featuring Houston Nobel Prize winner to air on PBS

to-watch list

Not all heroes wear capes. In fact, our current coronavirus heroes are donning face masks as they save lives. One local health care hero has a different disease as his enemy, and you'll soon be able to stream his story.

Dr. James "Jim" Allison won the 2018 Nobel Prize in Physiology or Medicine for his work in battling cancer by treating the immune system — rather than the tumor. Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center, has quietly and often, singularly, waged war with cancer utilizing this unique approach.

The soft-spoken trailblazer is the subject of an award-winning documentary, Jim Allison: Breakthrough, which will air on PBS and its streaming channels on Monday, April 27 at 9 pm (check local listings for channel information). Lauded as "the most cheering film of the year" by the Washington Post, the film follows Allison's personal journey to defeat cancer, inspired and driven by the disease killed his mother.

Breakthrough is narrated by Woody Harrelson and features music by Willie Nelson, adding a distinct hint of Texana. (The film was a star at 2019's South by Southwest film festival.) The documentary charts Alice, Texas native as he enrolls at the University of Texas, Austin and ultimately, cultivates an interest in T cells and the immune system — and begins to frequent Austin's legendary music scene. Fascinated by the immune system's power to protect the body from disease, Allison's research soon focuses on how it can be used to treat cancer.

Viewers will find Allison charming, humble, and entertaining: the venerable doctor is also an accomplished blues harmonica player. Director Bill Haney weaves Allison's personal story with the medical case of Sharon Belvin, a patient diagnosed with melanoma in 2004 who soon enrolled in Allison's clinical trials. Belvin has since been entirely cancer-free, according to press materials.

"We are facing a global health challenge that knows no boundaries or race or religion, and we are all relying on gifted and passionate scientists and healthcare workers to contain and ultimately beat this thing," said Haney, in a statement. "Jim Allison and the unrelenting scientists like him are my heroes – and I'll bet they become yours!"

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App.

------

This article originally ran on CultureMap.

Jim Allison, immunotherapy researcher at MD Anderson and Nobel Prize recipient, is the subject of a new film that premiered at SXSW. Photo courtesy of MD Anderson Cancer Center

Film about Nobel Prize-winning Houston scientist premieres at SXSW

Now showing

For most of his career, James Allison has been a cancer research wildcatter fighting an oftentimes lonely battle for the advancement of immunotherapy. The medical community has historically been skeptical of the science, but nonetheless Allison dedicated his life to developing a better treatment to the disease that has claimed so many lives — including his mother's.

Last year, Allison, the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson, won the 2018 Nobel Prize in medicine, and Breakthrough, a film about Allison's progression from early researcher to Nobel Prize recipient, premiered on March 9 at the 2019 SXSW Interactive festival.

But despite the Nobel Prize and the new film both validating the science to the public, Allison says there's a lot more work to be done in immunotherapy. Allison, his colleague, Padmanee Sharma, and the filmmaker for Breakthrough, Bill Haney, hosted a discussion at SXSW about the future of immunotherapy.

"It's a time of considerable optimism — and we're just at the beginning," says Allison.

The film focuses on the man behind the science — a 70-year-old, harmonica-playing researcher from small-town Alice, Texas. It's both an ode to Allison's career and a thought-provoking take on all the work left to be done in the industry.

Immunotherapy is the process of targeting one's immune system's T-cells, infection-fighting white blood cells, to attack cancer cells. Sharma, a fellow MD Anderson oncology expert and clinician, says their work has received clinical approvals for treating Melanoma, kidney cancer, lung cancer, and bladder cancer. The scientists are now focused on expanding that treatment to other cancer types and building upon the established platform they've created, while also making sure nothing comes in the way of the facts of the science.

"It really requires that we dedicate ourselves to the basic science, understanding it and educating people about it, so we don't allow the facts and science get muddied by things that are political or nonfactual," Sharma says.

In a lot of ways, this is what Breakthrough has been able to do — communicate the facts on a platform where anyone can understand the science.

"We have a revolution on our hands, and thankfully we have people like Bill who can really tell the story well, because maybe as a scientist and a clinician, we're not always equally talented on telling the story to laypeople," Sharma says.

Moving forward, Allison says he's focused on finding out why the treatment fails in some instances, and he's determined to progress immunotherapy's success rate from the 20 to 40 percent rate he says he sees it at now to 100 percent.

"We've got all the basic tools, and we know what the main issues are," Allison says. "There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

Jim Allison's groundbreaking work with T cells helped him net the award. Photo courtesy of MD Anderson Cancer Center

Houston scientist wins Nobel Prize for breakthrough cancer treatment

Research Recognition

A University of Texas MD Anderson Cancer Center scientist has been lauded for his cancer research. Jim Allison, Ph.D., was announced as the recipient of the 2018 Nobel Prize in Physiology or Medicine on October 1.

Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform, is the first MD Anderson scientist to receive the world's most coveted award for discoveries in the fields of life sciences and medicine. Allison won for his work in launching an effective new way to attack cancer by treating the immune system rather than the tumor, according to a release.

"I'm honored and humbled to receive this prestigious recognition," Allison says in a statement. "A driving motivation for scientists is simply to push the frontiers of knowledge. I didn't set out to study cancer, but to understand the biology of T cells, these incredible cells to travel our bodies and work to protect us."

Allison shares the award with Tasuku Honjo, M.D., Ph.D., of Kyoto University in Japan. When announcing the honor, the Nobel Assembly of Karolinska Institute in Stockholm noted in a statement that "stimulating the ability of our immune system to attack tumor cells, this year's Nobel Prize laureates have established an entirely new principle for cancer therapy."

The prize recognizes Allison's basic science discoveries on the biology of T cells, the adaptive immune system's soldiers, and his invention of immune checkpoint blockade to treat cancer. According to MD Anderson, Allison's crucial insight was to block a protein on T cells that acts as a brake on their activation, freeing the T cells to attack cancer. He developed an antibody to block the checkpoint protein CTLA-4 and demonstrated the success of the approach in experimental models.

Allison's work led to the development of the first immune checkpoint inhibitor drug which would become the first to extend the survival of patients with late-stage melanoma. Follow-up studies show 20 percent of those treated live for at least three years, with many living for 10 years and beyond, unprecedented results, according to the cancer center.

"Jim Allison's accomplishments on behalf of patients cannot be overstated," says MD Anderson president Peter WT Pisters, M.D., in a statement. "His research has led to life-saving treatments for people who otherwise would have little hope. The significance of immunotherapy as a form of cancer treatment will be felt for generations to come."

"I never dreamed my research would take the direction it has," Allison adds. "It's a great, emotional privilege to meet cancer patients who've been successfully treated with immune checkpoint blockade. They are living proof of the power of basic science, of following our urge to learn and to understand how things work."

---

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Digital Health Institute's new exec director aims to lead innovation and commercialization efforts

new hire

Though our existences have become deeply entangled with technology, our health has been slower to catch up. The creation late last year of the Digital Health Institute was a major step into the future for both Rice University and Houston Methodist, for whom the institute is a joint venture.

The latest news for the Digital Health Institute is the appointment of Pothik Chatterjee to the role of executive director.

“The Digital Health Institute’s collaborative model is uniquely powerful,” Chatterjee told Rice University’s office of media relations. “By bringing together clinicians, engineers and entrepreneurs, we’re building an ecosystem designed to transform how care is delivered and experienced.”

Chatterjee’s role is to help grow the collaboration between the institutions, but the Digital Health Institute already boasts more than 20 active projects, each of which pairs Rice faculty and Methodist clinicians.

“Research is great, but what we really want at the Digital Health Institute is to translate those research findings into products and services that can be used at the patient's bedside,” Chatterjee explained to InnovationMap.

Once the research is in place, it’s up to Chatterjee to find commercial opportunities within the research portfolio. Those include everything from hospital-grade medical imaging wearables to the creation of digital twins for patients to help better treat them.

“As we move from vision to execution, Pothik’s expertise will be essential in helping us strengthen the institutional alignment needed to deliver at scale,” Dr. Khurram Nasir, Methodist’s William A. Zoghbi Centennial Chair in Cardiovascular Medicine and division chief of cardiovascular prevention and wellness, told Rice. “From my vantage point of a health system, the real value lies not just in innovation, but in implementation.”

Nasir’s co-founder is Ashutosh Sabharwal, Rice’s Ernest Dell Butcher Professor of Engineering and professor of electrical and computer engineering.

“The Digital Health Institute is a key step toward advancing health and health care for the benefit of humanity,” Sabharwal said. “We’re thrilled to welcome Pothik to our growing team. His background in health care innovation, research administration and venture investing will be instrumental in translating cutting-edge research into impactful digital health solutions. From leading innovation strategy and forging strong partnerships to driving fundraising and grant development, his leadership will help shape the institute’s long-term success.”

Though Chatterjee has previously worked around the country, including in Boston and Baltimore, he says he believes Houston is uniquely positioned to thrive in the digital health space.

“Houston is the best place to do it, because we have Rice and Houston Methodist,” he told InnovationMap. “[People] want to help keep that innovation in Houston, not just send it off to Silicon Valley or New York or Boston. There seems to be a lot of appetite from the philanthropic community to have homegrown Houston digital health innovation.”

Reliant’s smart new bundle puts energy savings + insights into one app

Two companies known for innovation in energy and home automation, Reliant and Vivint, have teamed up to launch the Smarter Home Bundle: a powerful new offering that simplifies home energy management and enhances everyday living for Texans.

With smart technology, seamless app integration, and added energy savings, this bundle marks a major leap forward in how homeowners manage their comfort, security, and electricity usage.

What’s included in the Smarter Home Bundle?
Qualifying current and new Reliant electricity customers can take advantage of this premium bundle, which includes:

  • A free Vivint Doorbell Camera Pro with Smart Deter™ technology that detects deliveries and deters theft
  • A free Vivint Smart Thermostat, designed to integrate with HVAC systems for efficient temperature control
  • White-glove professional installation from Vivint Smart Home Pros
  • Access to an exclusive Vivint app experience, combining smart device controls and personalized energy insights powered by Reliant

All this is included at no additional cost with enrollment in the Smarter Home Bundle.

 Reliant Smarter Home Bundle Let the pros handle installation.Photo courtesy of Reliant

A unified, smarter home

Reliant and Vivint, both NRG companies, are offering the Smarter Home Bundle as an all-in-one solution for customers looking to streamline home management. By combining smart home security features with advanced energy tools, users gain greater control, comfort, and peace of mind. With one app, customers can monitor their home, manage devices, and track energy use — anytime, anywhere.

According to recent NRG Consumer research, nearly 70% of people want a single platform to manage their smart homes. The Vivint app, which averages 16 daily interactions, delivers exactly that.

Designed for savings and simplicity
Energy efficiency isn’t just a buzzword — it’s a key feature of the Smarter Home Bundle. As more households adopt smart devices (45% in 2024, up from 10% a decade ago), this bundle gives users tools that help cut energy use and potentially lower bills. In fact, 72% of surveyed users cite savings as the top benefit of smart home technology after safety.

The Vivint Smart Thermostat plays a major role here. It not only learns users' habits but also integrates with Reliant’s Degrees of Difference program, adjusting temperatures slightly during peak electricity demand. These small changes can have a big impact on grid stability — especially in hot Texas summers — without sacrificing comfort. Customers remain in control at all times and can override temperature changes in the app or manually if needed.

 Reliant Smarter Home Bundle Manage everything with one app.Graphic courtesy of Reliant

Powering the future with virtual power plants
The Smarter Home Bundle also contributes to Reliant’s growing residential virtual power plant (VPP) network. VPPs are a forward-thinking approach to grid management that leverage small-scale energy resources — like smart thermostats, home batteries, and electric vehicles — to balance electricity demand across thousands of homes.

With Texas experiencing record-high energy loads (85 gigwatts in 2023), this kind of coordination is critical to ensuring a stable and reliable power grid, especially during extreme weather events.

“By bringing together innovative leaders like Reliant and Vivint, we are providing smarter, more efficient energy solutions for Texans,” says Mark Parsons, senior vice president, NRG Consumer. “The Reliant Smarter Home Bundle combines our electricity plans with advanced technology, empowering Texans to take control of their energy usage and simplify home management. We are excited to roll out additional features in the coming months at no cost, all designed to help our customers manage their home’s comfort, security, and energy usage, all in one place.”

Learn more and enroll here.

Houston startups win NASA funding for space tech projects

fresh funding

Three Houston startups were granted awards from NASA this month to develop new technologies for the space agency.

The companies are among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs, according to NASA.

Each selected company will receive $150,000 and, based on their progress, will be eligible to submit proposals for up to $850,000 in Phase II funding to develop prototypes.

The SBIR program lasts for six months and contracts small businesses. The Houston NASA 2025 SBIR awardees include:

Solidec Inc.

  • Principal investigator: Yang Xia
  • Proposal: Highly reliable and energy-efficient electrosynthesis of high-purity hydrogen peroxide from air and water in a nanobubble facilitated porous solid electrolyte reactor

Rarefied Studios LLC

  • Principal investigator: Kyle Higdon
  • Proposal: Plume impingement module for autonomous proximity operations

The STTR program contracts small businesses in partnership with a research institution and lasts for 13 months. The Houston NASA 2025 STTR awardees include:

Affekta LLC

  • Principal investigator: Hedinn Steingrimsson
  • Proposal: Verifiable success in handling unknown unknowns in space habitat simulations and a cyber-physical system

Solidec and Affekta have ties to Rice University.

Solidec extracts molecules from water and air, then transforms them into pure chemicals and fuels that are free of carbon emissions. It was co-founded by Rice professor Haotian Wang and and was an Innovation Fellow at Rice’s Liu Idea Lab for Innovation and Entrepreneurship. It was previouslt selected for Chevron Technology Ventures’ catalyst program, a Rice One Small Step grant, a U.S. Department of Energy grant, and the first cohort of the Activate Houston program.

Affekta, an AI course, AI assistance and e-learning platform, was a part of Rice's OwlSpark in 2023.